The Company's non-surgical gene therapy product candidates use technology, which include methods of gene therapy, therapeutic genes, and gene delivery vectors. The non-surgical cardiovascular gene therapy product candidates currently under development are Generx, Genvascor, Genevx, Genecor, Corgenic and Myocor. Revenues reflect decreased costs reimbursable to the company under the Schering AG agreement.
Higher loss reflects increased personnel and investor relations expenses.
All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Data and information is provided for informational purposes only, and is not intended for trading purposes.